BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31481040)

  • 1. Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report.
    Otani S; Nakayama R; Sekita T; Hirozane T; Asano N; Nishimoto K; Sasaki A; Okita H; Morioka H; Nakamura M; Matsumoto M
    BMC Cancer; 2019 Sep; 19(1):872. PubMed ID: 31481040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two Cases of Intraosseous Pseudomyogenic (Epithelioid Sarcoma-Like) Hemangioendothelioma With Unusual Features, Expanding the Clinicopathological Spectrum.
    Rekhi B; Rane S; Puri A
    Int J Surg Pathol; 2021 Jun; 29(4):454-461. PubMed ID: 32851904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
    Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
    Sørensen AL; Hansen RL; Jørgensen PH
    Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifocal primary pseudomyogenic hemangioendothelioma of bone managed with denosumab: A rare case with diagnostic and therapeutic challenge.
    Pasricha S; Sharma A; Pruthi M; Durga G; Jajodia A; Gupta G; Kamboj M; Gupta M; Mehta A
    J Cancer Res Ther; 2022; 18(3):817-819. PubMed ID: 35900565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
    Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
    World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical, radiologic and pathologic features of giant cell tumor of bone treated with denosumab].
    Gong LH; Liu WF; Ding Y; Zhang W; Yang YK; Yu F; Wong GQ; Huang XY; Niu XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):449-454. PubMed ID: 29886590
    [No Abstract]   [Full Text] [Related]  

  • 8. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
    Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
    J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Giant cell tumour of bone in the denosumab era.
    van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
    Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
    Tariq MU; Umer M; Khan Z; Saeed J; Siddiqui MA; Din NU
    Ann Diagn Pathol; 2020 Apr; 45():151479. PubMed ID: 32088577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
    Tsukamoto S; Tanaka Y; Mavrogenis AF; Kido A; Kawaguchi M; Errani C
    Clin Orthop Relat Res; 2020 May; 478(5):1076-1085. PubMed ID: 31794487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
    Reddy K; Ramirez L; Kukreja K; Venkatramani R
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab for Bone Giant Cell Tumor of the Distal Radius.
    Tsukamoto S; Mavrogenis AF; Tanzi P; Leone G; Ciani G; Righi A; Akahane M; Honoki K; Tanaka Y; Donati DM; Errani C
    Orthopedics; 2020 Sep; 43(5):284-291. PubMed ID: 32745221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
    Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
    Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab, a Potential Alternative to the Surgical Treatment of Distal Radius Giant Cell Tumor of Bone: Case Report.
    Park MJ; Ganjoo KN; Ladd AL
    J Hand Surg Am; 2015 Aug; 40(8):1620-4. PubMed ID: 25935517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASO Author Reflections: Preoperative Denosumab May Increase the Risk of Local Recurrence of Giant Cell Tumor of Bone after Curettage Surgery.
    Asano N; Horiuchi K
    Ann Surg Oncol; 2022 Jun; 29(6):4001. PubMed ID: 35169975
    [No Abstract]   [Full Text] [Related]  

  • 18. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
    Roitman PD; Jauk F; Farfalli GL; Albergo JI; Aponte-Tinao LA
    Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of pelvic giant cell tumor of bone, complete remission with denosumab: long duration of response.
    Bilgetekin I; Mammadkhanli O; Basal FB; Kandemir O; Canbay S; Oksuzoglu B
    Anticancer Drugs; 2020 Jun; 31(5):533-535. PubMed ID: 31743134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How safe and effective is denosumab for bone giant cell tumour?
    Errani C; Tsukamoto S; Mavrogenis AF
    Int Orthop; 2017 Nov; 41(11):2397-2400. PubMed ID: 28646421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.